Elixir: Elixir Medical Corporation: TCT 2024: Elixir Medical to Present Clinical Outcomes on Two Transformative Platforms Designed to Advance Cardiovascular Disease Treatment and Intervention

Late-breaking INFINITY-SWEDEHEART Randomized Clinical Trial (RCT) data evaluating DynamX Coronary Bioadaptor System's unique mechanism of action among patients with Acute Coronary Syndrome (ACS) a...